ArticleDiscover oncology2026
Identification of prognostic genes and development of a risk model for pancreatic cancer based on hypoxia- and lipid metabolism-related genes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) is associated with a poor prognosis and limited therapeutic options because most patients are diagnosed at an advanced stage. Hypoxia- and lipid metabolism-related genes (HLPGs) play important roles in cancer progression. This study aimed to identify HLPGs-based prognostic genes in PC and explore their potential mechanisms, thereby providing a scientific basis for clinical management.
methodsUnivariate and multivariate Cox regression analyses were performed using public transcriptomic data to identify hypoxia- and lipid metabolism-related prognostic genes in PC, and a prognostic model was subsequently constructed. The underlying mechanisms were further investigated using gene set enrichment analysis (GSEA), immune microenvironment profiling, and drug sensitivity analysis in the high-risk group (HRG) and low-risk group (LRG). In addition, single-cell RNA sequencing was used to identify key cell populations in PC.
resultsINPP4B, SLCO1B3, LIPH, TGM2, ACSL5, SLC2A1, and EPHX2 were identified as prognostic genes. EPHX2 was significantly downregulated in PC, whereas the other six genes were upregulated. The prognostic model showed moderate predictive performance in the validation datasets. Pathway enrichment analysis revealed significant enrichment in the ribosome, ECM-receptor interaction, and focal adhesion pathways. Immune infiltration analysis showed that regulatory T cells were positively correlated with both myeloid-derived suppressor cells (MDSCs) and T follicular helper cells. LIPH showed the strongest correlations with type 17 T helper cells and central memory CD4 T cells. HRG patients were predicted to be more sensitive to the top 10 candidate drugs, including entinostat and sorafenib, and LIPH was positively correlated with sabutoclax_1849 and AZD8055_1059. ScRNA-seq identified ductal cells as the key cell type in PC, which were further clustered into 8 subsets.
conclusionINPP4B, SLCO1B3, LIPH, TGM2, ACSL5, SLC2A1, and EPHX2 were identified as hypoxia- and lipid metabolism-related prognostic genes in PC. Distinct immune cell subsets were also characterized during PC progression. These findings provide a foundation for further mechanistic studies and potential prognostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.